Immuno-Isolation in Oncology - A Mini-Review

Authors: Cirone P.; Saller R.M.; Chang P.L.

Source: Current Pharmaceutical Biotechnology, Volume 2, Number 3, September 2001 , pp. 269-277(9)

Publisher: Bentham Science Publishers

Abstract:

Immuno-isolation provides a potentially safe and effective method of delivering recombinant therapeutic molecules. Its application as a drug-delivery platform for the treatment of cancer has shown promising developments recently. This review will summarize the principle and current progress of this novel therapy paradigm in oncology. In this approach, a non-autologous cell line is genetically modified to secrete a recombinant product with potential for tumor suppression. Such a cell line may be implanted without graft rejection into all patients with similar neoplastic disease. The immune protection is conferred by enclosure within immuno-isolating devices such as microcapsules whose permeability would allow passage of smaller molecules such as oxygen, nutrients and waste products as well as the desired therapeutic transgene product. However, large immune mediators such as complement, macrophages and lymphocytes responsible for graft rejection would be excluded. In this review, we will consider how this technology may be applied as a novel genetic tool for cancer treatment to deliver antibodies, cytokines, enzymes and growth factors for treatment of various types of cancer. These molecules can be delivered at low constitutive levels, thereby permitting long-term systemic delivery, maintaining biological activity over extended periods, and eliminating the costs of product purification. The current success of this strategy in cancer treatment will be reviewed in in vitro systems, in animal models of cancer, and in human clinical trials.

Keywords: immuno-isolation; recomninant therapeutic molecules; cancer therapy; immunotherapy; cytokine; anti-angiogenesis; anti-angiogeneic factors; endostain; toxic metabolites; proteolytic enzyme inhibitors

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201013378680

Publication date: 2001-09-01

• Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

• In this: publication
• By this: publisher
• In this Subject: Nutrition & Food ,  Biotechnology ,  Pharmacology
• By this author: Cirone P. ;  Saller R.M. ;  Chang P.L.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers